Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 33Small Cell Lung Carcinoma 16Breast Neoplasms 13Sarcoma 9Carcinoma, Hepatocellular 8Esophageal Squamous Cell Carcinoma 7Lung Neoplasms 6Triple Negative Breast Neoplasms 5Ovarian Neoplasms 5Neoplasms 5Carcinoma 5Stomach Neoplasms 4Pheochromocytoma 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Nasopharyngeal Carcinoma 4Esophageal Neoplasms 4Colorectal Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Ovarian Epithelial 4Thyroid Neoplasms 3Recurrence 3Paraganglioma 3NSCLC 3Glioma 3Uterine Cervical Neoplasms 2Urogenital Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Platinum-resistant Ovarian Cancer 2Ovarian Diseases 2

Interventions

Etoposide 2olaparib 1ceralasertib 1apatinib 1anlotinib 1Platinum 1Paclitaxel 1Immune Checkpoint Inhibitors 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × SCLC × anlotinib × Clear all
NCT04684017 2020-12-24

Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer

Shanghai Chest Hospital

Phase 2 Unknown
29 enrolled
Thoracic

SCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡